CompletedPhase 1NCT05717621
Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)
Studying Vulvar intraepithelial neoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ViMREX GmbH
- Principal Investigator
- Elena-Sophie Prigge, Dr.ViMREX GmbH
- Intervention
- VTD-101 ointment(drug)
- Enrollment
- 29 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2023 – 2025
Study locations (5)
- Universitätsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtshilfe, Augsburg, Bavaria, Germany
- Medizinische Hochschule Hannover Klinik für Frauenheilkunde und Geburtshilfe, Hanover, Lower Saxony, Germany
- St. Elisabeth Krankenhaus Köln, Klinik für Gynäkologie und Geburtshilfe, Cologne, Germany
- Frauenarztpraxis Heussweg Hamburg, Hamburg, Germany
- Dysplasiezentrum HH am Krankenhaus Jerusalem, Hamburg, Germany
Collaborators
Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05717621 on ClinicalTrials.gov